More about

Atezolizumab

News
May 11, 2022
1 min read
Save

Phase 3 trial of combination for advanced lung cancer misses co-primary endpoint

Phase 3 trial of combination for advanced lung cancer misses co-primary endpoint

A randomized phase 3 trial designed to evaluate tiragolumab plus atezolizumab for certain patients with advanced lung cancer failed to meet its co-primary endpoint of PFS, topline data showed.

News
March 25, 2022
2 min read
Save

Atezolizumab safe before, during chemoradiation, active in women with cervical cancer

Atezolizumab safe before, during chemoradiation, active in women with cervical cancer

Atezolizumab administered before and during chemoradiation appeared safe and demonstrated immune-modulating activity among women with node-positive locally advanced cervical cancer, according to study results.

News
October 15, 2021
1 min read
Save

FDA approves Tecentriq for new lung cancer indication

FDA approves Tecentriq for new lung cancer indication

The FDA expanded the approval of atezolizumab to include adjuvant treatment of certain patients with non-small cell lung cancer.

News
September 30, 2021
2 min watch
Save

VIDEO: IMpower010 results 'first demonstration' of benefits from atezolizumab in certain patients with lung cancer

VIDEO: IMpower010 results 'first demonstration' of benefits from atezolizumab in certain patients with lung cancer

In this video, Pasi A. Jänne, MD, PhD, director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School, discusses results from the IMpower010 study presented at ESMO 2021.

News
September 24, 2021
3 min read
Save

Relapse patterns similar with atezolizumab or best supportive care in NSCLC subgroups

Relapse patterns similar with atezolizumab or best supportive care in NSCLC subgroups

Patients with early-stage non-small cell lung cancer who received best supportive care vs. atezolizumab after adjuvant chemotherapy had a higher relapse rate, but relapse patterns appeared similar between the groups, study results showed.

News
September 13, 2021
2 min read
Save

Atezolizumab regimen safe for resectable mesothelioma

Atezolizumab regimen safe for resectable mesothelioma

Use of atezolizumab as part of neoadjuvant therapy and again as maintenance met predetermined safety criteria for patients with resectable pleural mesothelioma, according to study results.

News
September 10, 2021
2 min read
Save

Atezolizumab regimen active in NSCLC with untreated brain metastases

Atezolizumab regimen active in NSCLC with untreated brain metastases

The combination of atezolizumab, carboplatin and pemetrexed demonstrated encouraging activity among patients with nonsquamous non-small cell lung cancer and untreated, asymptomatic brain metastases, according to phase 2 study results.

News
September 10, 2021
2 min read
Save

Adjuvant atezolizumab extends DFS for broad range of patients with stage II-IIIA NSCLC

Adjuvant atezolizumab extends DFS for broad range of patients with stage II-IIIA NSCLC

Adjuvant atezolizumab improved DFS among patients with non-small cell lung cancer with nodal involvement, according to study results.

News
August 27, 2021
1 min read
Save

Genentech withdraws accelerated approval of atezolizumab regimen for breast cancer subset

Genentech withdraws accelerated approval of atezolizumab regimen for breast cancer subset

Genentech has decided to voluntarily withdraw its accelerated approval of atezolizumab plus nab-paclitaxel for treatment of PD-L1-positive, unresectable locally advanced or metastatic triple-negative breast cancer.

News
August 12, 2021
1 min read
Save

Top in hem/onc: Right to Try vs. Expanded Access, priority review of thyroid cancer drug

Top in hem/onc: Right to Try vs. Expanded Access, priority review of thyroid cancer drug

Recent data revealed the Right to Try track did not more successfully help oncologists obtain investigational drugs than Expanded Access, which has an extra step of receiving FDA authorization for each patient.

View more